(New York, USA) DelveInsight’s ‘Respiratory Syncytial Virus Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Respiratory Syncytial Virus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Respiratory Syncytial Virus pipeline domain.
Request a sample and discover the recent breakthroughs happening in the Respiratory Syncytial Virus pipeline landscape @ Respiratory Syncytial Virus Pipeline Outlook
Key Takeaways from the Respiratory Syncytial Virus Pipeline Report
Respiratory Syncytial Virus Overview
Respiratory syncytial virus (RSV) is a common cause of respiratory tract infection, especially in youngsters. By the age of four, nearly all children have been infected, with many infected during their first year of life. Because infection does not offer complete immunity, reinfection is common, albeit usually less severe. Outbreaks are most common in the winter and early spring. RSV is the most prevalent cause of lower respiratory tract infection in young infants, accounting for more than 50,000 hospitalizations in children under the age of five in the United States each year. The initial infection frequently proceeds from an upper respiratory tract disease with congestion and fever to the lower respiratory tract, causing bronchiolitis and, in rare cases, pneumonia with cough and difficulty breathing. Later infections often exclusively affect the upper respiratory tract. Children who have suffered bronchiolitis are more prone to develop asthma as they grow older.
Find out more about Respiratory Syncytial Virus medication @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight
Respiratory Syncytial Virus Treatment Analysis: Drug Profile
Nirsevimab (MEDI-8897): MedImmune
MEDI8897 is a monoclonal antibody (mAb) used to prevent lower respiratory tract sickness (LRTI) caused by respiratory syncytial virus (RSV), which is the most common cause of LRTI in newborns and young children. It is currently in phase III of development.
Sisunatovir: ReViral
Sisunatovir is an orally given fusion inhibitor that works by preventing RSV F-mediated fusion with the host cell. Preclinical studies revealed that sisunatovir has a low toxicity profile and a promising therapeutic index. Sisunatovir demonstrated excellent exposure in Phase 1 clinical investigations, with no significant side effects recorded. In 2018, the findings of Phase 2a challenge research in healthy adult volunteers revealed that sisunatovir reduced viral load and clinical symptoms statistically significantly. ReViral has begun two international multicenter Phase 2 clinical trials of sisunatovir in high-risk pediatric and adult patient populations.
Key Respiratory Syncytial Virus Therapies and Companies
Learn more about the novel and emerging Respiratory Syncytial Virus pipeline therapies @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight
Respiratory Syncytial Virus Therapeutics Assessment
Request for Sample Report @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight
Scope of the Respiratory Syncytial Virus Pipeline Report
Dive deep into rich insights for drugs used for Respiratory Syncytial Virus treatment; visit @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight
Table of Contents
1. Introduction
2. Executive Summary
3. Respiratory Syncytial Virus Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Respiratory Syncytial Virus Pipeline Therapeutics
6. Respiratory Syncytial Virus Pipeline: Late Stage Products (Phase III)
7. Respiratory Syncytial Virus Pipeline: Late Stage Products (Phase III)
8. Respiratory Syncytial Virus Pipeline: Mid-Stage Products (Phase II)
9. Respiratory Syncytial Virus Pipeline: Early Stage Products (Phase I)
10. Respiratory Syncytial Virus Therapeutic Assessment
11. Inactive Respiratory Syncytial Virus Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Respiratory Syncytial Virus Companies
14. Key Respiratory Syncytial Virus Products
15. Respiratory Syncytial Virus Unmet Needs
16. Respiratory Syncytial Virus Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting